摘要
TACE为治疗中期肝细胞癌(HCC)的标准方案,但术后肿瘤复发率较高,常需多次重复治疗,或可导致肝功能恶化。TACE联合其他治疗手段可使HCC患者临床获益增加,并逐渐受到关注。本文就TACE联合索拉非尼治疗中期HCC的TACTICS与SPACE方案相关研究进展进行综述。
TACE is the standard treatment plan for intermediate stage hepatocellular carcinoma(HCC),while postoperative tumor recurrence rate is high and repeated treatment is usually required,which may lead to deterioration of liver function.TACE combined with other treatment methods were used to increase the clinical benefits of HCC patients,and attracted attention in related fields.The progresses of TACE combining with sorafenib using TACTICS and SPACE for treating intermediate stage HCC were reviewed in this article.
作者
杨正强
YANG Zhengqiang(Department of Interventional Therapy, Cancer Hospital Chinese Academy of Medical Sciences , Beijing 100021, China)
出处
《中国介入影像与治疗学》
北大核心
2021年第12期748-752,共5页
Chinese Journal of Interventional Imaging and Therapy
基金
中国健康促进基金会“肿瘤介入科研基金”资助项目(XM_2018_001_006_01)。
关键词
癌
肝细胞
化学栓塞
治疗性
介入治疗
carcinoma
hepatocellular
chemoembolization,therapeutic
interventional therapy
